Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
B-Raf inhibitor 1 is a novel, potent and selective Raf kinase inhibitor, with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively. One of the growth signal transduction protein kinases in the Raf kinase family is B-Raf. This protein controls the MAP kinase/ERKs signaling pathway, which controls cell proliferation, differentiation, and secretion.
Targets |
B-Raf (Ki = 1 nM); B-RafV600E (Ki = 1 nM); c-Raf (Ki = 0.3 nM)
|
---|---|
ln Vitro |
Raf inhibitor 1 (Compound 13) inhibits the proliferation of A375 and HCT-116 with IC50 values of 0.31 and 0.72 M, respectively. The ATP pocket on B-Raf is partially filled by Phe595 and Gly596 from the DFG motif when Raf inhibitor 1 (Compound 13) binds to it and stabilizes it in a DFG-out, inactive conformation. Additionally, Raf inhibitor 1 (Compound 13) inhibits wild type B-Raf cell lines at low micromolar concentrations, which may be the result of pan-Raf inhibition, including Raf dimers, or alternatively off-target kinase activities[1].
|
References |
Molecular Formula |
C26H19CLN8
|
---|---|
Molecular Weight |
478.9357
|
Exact Mass |
478.14
|
Elemental Analysis |
C, 65.20; H, 4.00; Cl, 7.40; N, 23.40
|
CAS # |
1093100-40-3
|
Related CAS # |
Raf inhibitor 1 dihydrochloride;1191385-19-9
|
Appearance |
Solid powder
|
SMILES |
CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC=C(C=C3)Cl)NC4=C(C=CC=N4)C5=C6C(=NC=N5)N=CN6
|
InChi Key |
KKVYYGGCHJGEFJ-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C26H19ClN8/c1-15-4-9-19-18(10-12-29-24(19)34-17-7-5-16(27)6-8-17)21(15)35-25-20(3-2-11-28-25)22-23-26(32-13-30-22)33-14-31-23/h2-14H,1H3,(H,28,35)(H,29,34)(H,30,31,32,33)
|
Chemical Name |
1-N-(4-chlorophenyl)-6-methyl-5-N-[3-(7H-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine
|
Synonyms |
B-Raf Inhibitor 1; B-Raf-Inhibitor 1; B-Raf-Inhibitor-1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 50~96 mg/mL (104.4~200.4 mM)
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0879 mL | 10.4397 mL | 20.8794 mL | |
5 mM | 0.4176 mL | 2.0879 mL | 4.1759 mL | |
10 mM | 0.2088 mL | 1.0440 mL | 2.0879 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02967692 | Active Recruiting |
Biological: Spartalizumab Other: Placebo |
Melanoma | Novartis Pharmaceuticals | February 17, 2017 | Phase 3 |
NCT03026517 | Active Recruiting |
Drug: Dabrafenib Drug: Trametinib |
Melanoma | Memorial Sloan Kettering Cancer Center |
January 2017 | Phase 1 |
NCT03410875 | Active Recruiting |
Drug: Vemurafenib Drug: Obinutuzumab |
Leukemia Hairy Cell Leukemia |
Memorial Sloan Kettering Cancer Center |
February 9, 2018 | Phase 2 |
NCT04655157 | Active Recruiting |
Drug: encorafenib Drug: nivolumab |
Melanoma | Jason J. Luke, MD | May 28, 2021 | Phase 1 Phase 2 |
NCT03101254 | Active Recruiting |
Drug: LY3022855 Drug: Vemurafenib |
Melanoma | Dana-Farber Cancer Institute | June 6, 2017 | Phase 1 Phase 2 |